Advertisement

U.S. markets open in 4 hours 24 minutes

S&P Futures
4,621.50
+55.25(+1.21%)
Dow Futures
34,772.00
+315.00(+0.91%)
Nasdaq Futures
16,377.00
+226.50(+1.40%)
Russell 2000 Futures
2,245.50
+48.20(+2.19%)
Crude Oil
69.05
+2.87(+4.34%)
Gold
1,784.40
+7.90(+0.44%)

Advertisement

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD

Add to watchlist

0.1731

-0.0128

(-6.90%)

At close: 03:55PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.1859
Open	0.1916
Bid	0.0000 x 0
Ask	0.0000 x 0
Day's Range	0.1601 - 0.1922
52 Week Range	0.1110 - 0.4400
Volume	565,639
Avg. Volume	241,540

Market Cap	70.52M
Beta (5Y Monthly)	2.04
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0790
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

TETRA BIO PHARMA INC
CPE: Lowering target price to $11.00CALLON PETROLEUM CO has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
Rating
Fair Value
Economic Moat
11 months agoArgus Research

All

News

Press Releases

Research Reports

CNW Group
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that it received a letter from the United States Food and Drug Administration (FDA), granting a Type C meeting to discuss safety and labelling requirements for obtaining marketing approval under the 505(b)(1) regulatory pathway for its QIXLEEF™.
CNW Group
Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for cancer pain. QIXLEEF™ is a botanical inhaled investigational new drug with a fixed ratio of THC and CBD that meets USA cGMP regulatory requirements.
- Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma
  GlobeNewswire
- Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
  GlobeNewswire
PR Newswire
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, announced today the termination of its previously announced "at-the-market" equity offering program (the "ATM Program") with Canaccord Genuity Corp. as sole agent.